Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Common Equity: 2012-2025

Historic Common Equity for Ascendis Pharma A (ASND) over the last 9 years, with Sep 2025 value amounting to -$3.2 billion.

  • Ascendis Pharma A's Common Equity fell 12.69% to -$3.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 billion, marking a year-over-year decrease of 12.69%. This contributed to the annual value of -$114.4 million for FY2024, which is 27.02% up from last year.
  • Per Ascendis Pharma A's latest filing, its Common Equity stood at -$3.2 billion for Q3 2025, which was down 4.45% from -$3.0 billion recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Common Equity registered a high of $2.3 billion during Q2 2023, and its lowest value of -$3.2 billion during Q3 2025.
  • Its 3-year average for Common Equity is -$1.4 billion, with a median of -$2.6 billion in 2024.
  • Per our database at Business Quant, Ascendis Pharma A's Common Equity slumped by 112,904.77% in 2023 and then increased by 27.94% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Common Equity (Quarterly) stood at $1.0 billion in 2021, then plummeted by 73.42% to $268.7 million in 2022, then slumped by 158.34% to -$156.8 million in 2023, then grew by 27.94% to -$113.0 million in 2024, then fell by 12.69% to -$3.2 billion in 2025.
  • Its Common Equity was -$3.2 billion in Q3 2025, compared to -$3.0 billion in Q2 2025 and -$2.8 billion in Q1 2025.